Statistics for Amivantamab Plus Lazertinib Vs Osimertinib in First Line, Egfr-Mutant Advanced Nsclc: Patientrelevant Outcomes From Mariposa
Total visits
| views | |
|---|---|
| Amivantamab Plus Lazertinib Vs Osimertinib in First Line, Egfr-Mutant Advanced Nsclc: Patientrelevant Outcomes From Mariposa | 3 |
Total visits per month
| views | |
|---|---|
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 3 |
| February 2026 | 0 |
| March 2026 | 0 |
Top country views
| views | |
|---|---|
| India | 2 |
| Turkey | 1 |
Top city views
| views | |
|---|---|
| Pune | 2 |
| Eskişehir | 1 |